As economic and regulatory uncertainty loom over the 2025 TV upfronts, pharma marketers are rethinking how they show up across media. In Sam Bradley’s latest piece for Digiday, our EVP…
BranchLab CEO, Josh Walsh, weighs in on the role state regulations will play for marketers, especially pharma advertisers, in the vacuum of federal regulation.
BranchLab’s Michael Parkes predicts: “State privacy regulations, such as Washington’s My Health My Data Act, will profoundly reshape pharmaceutical advertising by imposing strict limitations on the use of health data….
BranchLab’s Michael Parkes provides an overview of the emerging state regulations impacting the media strategies of pharmaceutical and healthcare brands, offering recommendations on how to navigate a new era of…
BranchLab CEO, Josh Walsh, weighs in on Meta’s move to implement stricter policies for health and wellness brands.
Does the incoming Trump administration and RFK Jr.’s potential appointment as the head of Health and Human Services (HHS) spell the end of TV drug ads? Probably not, argues Josh Walsh, CEO…
President-elect Donald Trump named Robert F. Kennedy Jr. as his pick to run the Department of Health and Human Services (HHS) when he returns to the White House. Kennedy has…
